File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A prospective, randomized, double-blind study to compare two doses of recombinant human chorionic gonadotropin in inducing final oocyte maturity and the hormonal profile during the luteal phase

TitleA prospective, randomized, double-blind study to compare two doses of recombinant human chorionic gonadotropin in inducing final oocyte maturity and the hormonal profile during the luteal phase
Authors
Issue Date2005
PublisherThe Endocrine Society. The Journal's web site is located at http://jcem.endojournals.org
Citation
Journal Of Clinical Endocrinology And Metabolism, 2005, v. 90 n. 7, p. 3933-3938 How to Cite?
AbstractContext: Different doses of human chorionic gonadotropin (hCG) have been used in various in vitro fertilization (IVF) treatment protocols to achieve final oocyte maturation. There is as yet no agreement on the optimum dose required. Objectives: The objective of this study was to compare the effectiveness of 250 and 500 μg recombinant hCG (r-hCG), which represented the lower and upper limits of the dose range, in inducing final oocyte maturation during IVF and intracytoplasmic sperm injection cycles. Design: This was a prospective, randomized, double-blind study. Setting: This study was performed at an IVF clinic in a teaching hospital. Patients: Sixty patients with an indication for intracytoplasmic sperm injection were studied. Intervention: The treatment dose used was 250 or 500 μg r-hCG. Main Outcome Measures: The percentage of metaphase II oocytes retrieved per patient, as an indicator of oocyte maturation, and the hormone profiles of the treatment cycle starting from the day of hCG up to hCG+10 d were the main outcome measures. Results: The percentage of metaphase II oocytes was similar in the two groups (89.3% vs. 86.0%; P = 0.326) despite higher serum and follicular fluid hCG levels on hCG+2 and hCG+4 d, as was the follicular fluid to serum hCG ratio in the 500-μg r-hCG group. Serum estradiol and progesterone levels were comparable initially, but became significantly higher in the 500-μg r-hCG group on hCG+10 d. Conclusion: The two doses of r-hCG were equally effective in inducing final oocyte maturation. It remains unclear whether the higher midluteal estradiol and progesterone levels in the 500-μg r-hCG group confer any benefit. Copyright © 2005 by The Endocrine Society.
Persistent Identifierhttp://hdl.handle.net/10722/87449
ISSN
2015 Impact Factor: 5.531
2015 SCImago Journal Rankings: 2.940
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChan, CCWen_HK
dc.contributor.authorNg, EHYen_HK
dc.contributor.authorTang, OSen_HK
dc.contributor.authorYeung, WSBen_HK
dc.contributor.authorLau, EYLen_HK
dc.contributor.authorHo, PCen_HK
dc.date.accessioned2010-09-06T09:29:48Z-
dc.date.available2010-09-06T09:29:48Z-
dc.date.issued2005en_HK
dc.identifier.citationJournal Of Clinical Endocrinology And Metabolism, 2005, v. 90 n. 7, p. 3933-3938en_HK
dc.identifier.issn0021-972Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/87449-
dc.description.abstractContext: Different doses of human chorionic gonadotropin (hCG) have been used in various in vitro fertilization (IVF) treatment protocols to achieve final oocyte maturation. There is as yet no agreement on the optimum dose required. Objectives: The objective of this study was to compare the effectiveness of 250 and 500 μg recombinant hCG (r-hCG), which represented the lower and upper limits of the dose range, in inducing final oocyte maturation during IVF and intracytoplasmic sperm injection cycles. Design: This was a prospective, randomized, double-blind study. Setting: This study was performed at an IVF clinic in a teaching hospital. Patients: Sixty patients with an indication for intracytoplasmic sperm injection were studied. Intervention: The treatment dose used was 250 or 500 μg r-hCG. Main Outcome Measures: The percentage of metaphase II oocytes retrieved per patient, as an indicator of oocyte maturation, and the hormone profiles of the treatment cycle starting from the day of hCG up to hCG+10 d were the main outcome measures. Results: The percentage of metaphase II oocytes was similar in the two groups (89.3% vs. 86.0%; P = 0.326) despite higher serum and follicular fluid hCG levels on hCG+2 and hCG+4 d, as was the follicular fluid to serum hCG ratio in the 500-μg r-hCG group. Serum estradiol and progesterone levels were comparable initially, but became significantly higher in the 500-μg r-hCG group on hCG+10 d. Conclusion: The two doses of r-hCG were equally effective in inducing final oocyte maturation. It remains unclear whether the higher midluteal estradiol and progesterone levels in the 500-μg r-hCG group confer any benefit. Copyright © 2005 by The Endocrine Society.en_HK
dc.languageengen_HK
dc.publisherThe Endocrine Society. The Journal's web site is located at http://jcem.endojournals.orgen_HK
dc.relation.ispartofJournal of Clinical Endocrinology and Metabolismen_HK
dc.rightsJournal of Clinical Endocrinology and Metabolism. Copyright © The Endocrine Society.en_HK
dc.titleA prospective, randomized, double-blind study to compare two doses of recombinant human chorionic gonadotropin in inducing final oocyte maturity and the hormonal profile during the luteal phaseen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0021-972X&volume=90&issue=7&spage=3933&epage=3938&date=2005&atitle=A+prospective,+randomized,+double-blind+study+to+compare+two+doses+of+recombinant+human+chorionic+gonadotropin+in+inducing+final+oocyte+maturity+and+the+hormonal+profile+during+the+luteal+phaseen_HK
dc.identifier.emailNg, EHY:nghye@hkucc.hku.hken_HK
dc.identifier.emailYeung, WSB:wsbyeung@hkucc.hku.hken_HK
dc.identifier.emailHo, PC:pcho@hku.hken_HK
dc.identifier.authorityNg, EHY=rp00426en_HK
dc.identifier.authorityYeung, WSB=rp00331en_HK
dc.identifier.authorityHo, PC=rp00325en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1210/jc.2004-2169en_HK
dc.identifier.pmid15870129-
dc.identifier.scopuseid_2-s2.0-23044463591en_HK
dc.identifier.hkuros115073en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-23044463591&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume90en_HK
dc.identifier.issue7en_HK
dc.identifier.spage3933en_HK
dc.identifier.epage3938en_HK
dc.identifier.isiWOS:000230339100017-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridChan, CCW=26643394500en_HK
dc.identifier.scopusauthoridNg, EHY=35238184300en_HK
dc.identifier.scopusauthoridTang, OS=7006723402en_HK
dc.identifier.scopusauthoridYeung, WSB=7102370745en_HK
dc.identifier.scopusauthoridLau, EYL=7103086093en_HK
dc.identifier.scopusauthoridHo, PC=7402211440en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats